Safety of enteral naloxone and i.v. neostigmine when used to relieve constipation.
Thomas
Michael C
MC
Department of Pharmacy Services, Munson Medical Center, Traverse City, MI, USA.
Erstad
Brian L
BL
D000284:Administration, Oral; D000285:Administration, Rectal; D000293:Adolescent; D000328:Adult; D000368:Aged; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D003085:Colic / Q000139:chemically induced; D003248:Constipation / Q000188:drug therapy*; D004244:Dizziness / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007022:Hypotension / Q000139:chemically induced; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007441:Intubation, Gastrointestinal / Q000379:methods; D008297:Male; D008875:Middle Aged; D009270:Naloxone / Q000008:administration & dosage* / Q000009:adverse effects; D009292:Narcotic Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D009325:Nausea / Q000139:chemically induced; D009388:Neostigmine / Q000008:administration & dosage* / Q000009:adverse effects; D010277:Parasympathomimetics / Q000008:administration & dosage* / Q000009:adverse effects; D012189:Retrospective Studies; D016896:Treatment Outcome
D009292:Narcotic Antagonists; D010277:Parasympathomimetics; D009270:Naloxone; D009388:Neostigmine